CD22-targeted glyco-engineered natural killer cells offer a further treatment option for B-cell acute lymphoblastic leukemia

Haematologica. 2024 May 2. doi: 10.3324/haematol.2023.284241. Online ahead of print.ABSTRACTNot available.PMID:38695137 | DOI:10.3324/haematol.2023.284241

Source: Haematologica - May 2, 2024 Category: Hematology Authors: Xin Jin Rui Sun Zhu Li Xianwu Wang Xia Xiong Wenyi Lu Hairong Lyu Xia Xiao Yunpeng Tian Hongkai Zhang Zhihong Fang Luqiao Wang Mingfeng Zhao Source Type: research